STOCK TITAN

Edwards Lifesciences (NYSE: EW) CEO stock sale, gifts and updated holdings

(High)
(Negative)
Form Type
4

Rhea-AI Filing Summary

Edwards Lifesciences Corp CEO Bernard J. Zovighian reported several Common Stock transactions dated July 27, 2026. He made bona fide gifts totaling 639.2998 shares, moving 319.6499 shares out of direct ownership and 319.6499 shares into a trust, while an affiliated trust sold 2,920.5511 shares at $83.9342 per share. Following these changes, he directly held 98,845 shares, with an additional 3,733.5603 shares held indirectly through a 401(k).

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider Zovighian Bernard J
Role CEO
Sold 2,920.5511 shs ($245K)
Type Security Shares Price Value
Gift Common Stock 319.6499 $0.00 $0.00
Gift Common Stock 319.6499 $0.00 $0.00
Sale Common Stock 2,920.5511 $83.9342 $245K
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 98,845 shares (Direct); Common Stock — 8,915.6499 shares (Indirect, By Trust); Common Stock — 3,733.5603 shares (Indirect, 401(k))
Shares sold 2,920.5511 shares Common Stock sold indirectly by trust on July 27, 2026
Sale price $83.9342 per share Price for the 2,920.5511 Common Stock shares sold by trust
Gifted shares 639.2998 shares Total bona fide gift transfers of Common Stock on July 27, 2026
Direct holdings after 98,845 shares Directly owned Common Stock following July 27, 2026 transactions
401(k) holdings 3,733.5603 shares Indirect Common Stock holdings via 401(k) after reported transactions
Bona fide gift financial
"Transaction code G is described as a "Bona fide gift" of Common Stock."
A bona fide gift is a genuine, voluntary transfer of money, property, or benefits from one party to another made without expectation of repayment, services, or hidden conditions. Investors care because such gifts can affect company disclosures, related‑party transaction rules, tax treatment, and perceived conflicts of interest; think of it like someone giving you a present with no strings attached — but on a corporate scale, auditors and regulators need to verify it really is unconditional.
beneficial ownership financial
"The remarks state the form reflects changes in beneficial ownership only."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
indirect ownership financial
"Some Common Stock is reported as indirect ownership, including shares held by a trust."
401(k) financial
"An indirect holding of Common Stock is reported as held through a 401(k)."
A 401(k) is a type of retirement savings plan offered by employers that allows workers to set aside a portion of their paycheck before taxes are taken out. The money saved in a 401(k) can grow over time through investments, helping individuals build funds for their future retirement. It matters to investors because it provides a tax-advantaged way to save and invest for long-term financial security.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider stock transactions did Edwards Lifesciences (EW) CEO Bernard J. Zovighian report?

Bernard J. Zovighian reported bona fide gifts totaling 639.2998 shares of Edwards Lifesciences Common Stock and an indirect sale of 2,920.5511 shares by a trust on July 27, 2026, along with updated direct and 401(k) holdings.

How many Edwards Lifesciences (EW) shares did the CEO sell, and at what price?

An affiliated trust for the CEO sold 2,920.5511 shares of Edwards Lifesciences Common Stock at a price of $83.9342 per share on July 27, 2026, as reported in the Form 4 filing.

What gifts of Edwards Lifesciences (EW) stock did the CEO report?

The filing shows bona fide gifts of 639.2998 shares of Edwards Lifesciences Common Stock, consisting of 319.6499 shares disposed from direct ownership and 319.6499 shares acquired by a trust, all dated July 27, 2026.

What are Bernard J. Zovighian’s holdings in Edwards Lifesciences (EW) after these transactions?

After the reported transactions, Bernard J. Zovighian directly held 98,845 shares of Edwards Lifesciences Common Stock and indirectly held 3,733.5603 shares through a 401(k), in addition to other indirect trust holdings reported in the Form 4.

Were the Edwards Lifesciences (EW) CEO’s reported transactions under a Rule 10b5-1 trading plan?

The Form 4 data indicate the Rule 10b5-1 trading plan checkbox was not marked as affirmatively adopted, so the reported sale and gifts are not identified as executed under a Rule 10b5-1 trading plan.

How is indirect ownership reported for the Edwards Lifesciences (EW) CEO in this Form 4?

The filing shows indirect ownership "By Trust" for both gifted and sold shares, and a separate indirect holding of 3,733.5603 shares through a 401(k), distinguishing these from the CEO’s directly owned 98,845 shares.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Zovighian Bernard J

(Last)(First)(Middle)
ONE EDWARDS WAY

(Street)
IRVINE CALIFORNIA 92614

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/27/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/27/2026G319.6499D$0.000098,845D
Common Stock07/27/2026G319.6499A$0.000011,836.201IBy Trust
Common Stock07/27/2026S2,920.5511D$83.93428,915.6499IBy Trust
Common Stock3,733.5603I401(k)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
Remarks:
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.
Linda J. Park, Attorney-in-Fact07/27/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)